William Blair Issues Optimistic Outlook for Incyte Earnings

Incyte Co. (NASDAQ:INCY) – Equities researchers at William Blair lifted their Q4 2025 earnings per share estimates for shares of Incyte in a note issued to investors on Tuesday, April 29th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will earn $1.25 per share for the quarter, up from their prior forecast of $1.16. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share.

Several other research firms have also commented on INCY. Citigroup lowered their price target on shares of Incyte from $97.00 to $88.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. JMP Securities reissued a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. Guggenheim cut Incyte from a “buy” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Tuesday, March 18th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. Finally, Wells Fargo & Company lifted their target price on shares of Incyte from $58.00 to $59.00 and gave the stock an “equal weight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $73.53.

Incyte Price Performance

Shares of NASDAQ INCY opened at $62.53 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The stock has a market cap of $12.10 billion, a price-to-earnings ratio of 231.60, a PEG ratio of 0.41 and a beta of 0.89. The company’s 50-day moving average price is $62.53 and its 200 day moving average price is $68.85. Incyte has a 52 week low of $52.73 and a 52 week high of $83.95.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.15. The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $996.17 million. Incyte had a return on equity of 0.05% and a net margin of 0.77%. Incyte’s revenue was up 19.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 earnings per share.

Hedge Funds Weigh In On Incyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWA Asset Management Group LLC acquired a new position in shares of Incyte in the fourth quarter worth about $1,933,000. Wells Fargo & Company MN increased its holdings in Incyte by 61.3% during the 4th quarter. Wells Fargo & Company MN now owns 174,190 shares of the biopharmaceutical company’s stock worth $12,031,000 after purchasing an additional 66,220 shares during the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Incyte in the 4th quarter valued at approximately $1,006,000. JPMorgan Chase & Co. boosted its stake in shares of Incyte by 13.5% during the 4th quarter. JPMorgan Chase & Co. now owns 323,640 shares of the biopharmaceutical company’s stock valued at $22,354,000 after buying an additional 38,550 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Incyte by 262.2% during the fourth quarter. SG Americas Securities LLC now owns 99,407 shares of the biopharmaceutical company’s stock worth $6,866,000 after buying an additional 71,963 shares in the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Sheila A. Denton sold 599 shares of Incyte stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total transaction of $41,924.01. Following the sale, the executive vice president now owns 25,848 shares in the company, valued at $1,809,101.52. This trade represents a 2.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of the company’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the transaction, the executive vice president now owns 33,567 shares of the company’s stock, valued at $2,272,150.23. This trade represents a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,475 shares of company stock valued at $2,424,751. Company insiders own 17.60% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.